Trial Profile
Phase I Dose Escalation Study of Temozolomide With Autologous Stem Cell Rescue for Patients With Relapsed/Refractory CNS Malignancy Including Isolated Metastatic Disease.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 May 2012
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 26 Apr 2012 Actual patient number is 2 according to ClinicalTrials.gov.
- 26 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.